Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulmatrix Inc (PULM)

Pulmatrix Inc (PULM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,878
  • Shares Outstanding, K 3,650
  • Annual Sales, $ 7,810 K
  • Annual Income, $ -9,560 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.58
  • Price/Sales 4,991.46
  • Price/Cash Flow N/A
  • Price/Book 1.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.90 +5.13%
on 12/05/25
4.98 -17.67%
on 11/17/25
-0.61 (-12.95%)
since 11/14/25
3-Month
3.90 +5.13%
on 12/05/25
5.50 -25.43%
on 10/06/25
-0.99 (-19.45%)
since 09/16/25
52-Week
3.90 +5.13%
on 12/05/25
10.40 -60.58%
on 02/18/25
-1.94 (-32.12%)
since 12/16/24

Most Recent Stories

More News
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSEâ„¢, which enables delivery of small- or large-molecule...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Proposed merger anticipated to close in 2025

PULM : 4.10 (-5.75%)
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 4.10 (-5.75%)
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)
Pulmatrix Supports World Asthma Day 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 4.10 (-5.75%)

Business Summary

Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease...

See More

Key Turning Points

3rd Resistance Point 4.50
2nd Resistance Point 4.42
1st Resistance Point 4.26
Last Price 4.10
1st Support Level 4.02
2nd Support Level 3.94
3rd Support Level 3.78

See More

52-Week High 10.40
Fibonacci 61.8% 7.92
Fibonacci 50% 7.15
Fibonacci 38.2% 6.38
Last Price 4.10
52-Week Low 3.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar